Biofrontera Inc. (the ?Company?) announced amendment No. 1 on Form 8-K/A (this ?Amendment?) is being filed by the company to amend the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on December 28, 2023 (the ?Original Form 8-K?). The Original Form 8-K reported, among other things, that the Company was in the process of terminating the revolving line of credit between the Company and MidCap Business Credit LLC (?MidCap?) that provided for maximum borrowings of $6.5 million, subject to a borrowing base and an availability block (the ?MidCap Loan Agreement?).

At the time of the Original Form 8-K, the Company had not finalized the termination of the MidCap Loan Agreement. The Amendment is being filed solely to report the completion of such termination. Other than providing the additional information, no other disclosure in the Original Form 8-K is amended, updated, or changed by this Form 8-K/A. Effective as of January 4, 2024, the Company terminated the MidCap Loan Agreement.

In connection with the termination, the Company paid a $150,000 prepayment fee to MidCap. As reported in the Original Form 8-K, the Company terminated the MidCap Loan Agreement in connection with entering into Agreement A and Agreement B.